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INTRODUCTION 
Gerald Reaven in the year 1988, reintroduced the concept of 
Syndrome X for the clustering of cardiovascular risk factors like 
hypertension, glucose intolerance, high triglycerides and low HDL 
cholesterol concentrations.36,58 The syndrome however is much older and 
has been described by Kylin in the year 192336. He found hypertension, 
hyperglycaemia and gout to cluster together as a syndrome and such an 
association has been quoted by researchers subsequently. Clustering 
analyses have confirmed that these traits occur simultaneously to a greater 
degree than would be expected by chance alone. 50,51,60,72 Thereafter, 
several other metabolic abnormalities have been associated with the 
syndrome, including obesity, microalbuminuria and abnormalities in 
fibrinolysis and coagulation.5,28,52,73 
 
The term metabolic syndrome was coined by German researchers 
including Haller and colleagues.3,33,61 In 1991, Ferrannini et.al.23 described 
the same clustering of abnormalities in this cardiovascular and metabolic 
syndrome as being caused by insulin resistance and concluded that 
“insulin resistance syndrome” was the appropriate term for the condition. 
The metabolic syndrome has also been given other names including the 
plurimetabolic syndrome and the deadly quartet.7,15,17,38 
1
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Because of the epidemic of overweight and sedentary lifestyle 
worldwide, the metabolic syndrome is becoming increasingly common.71 
According to the NCEP definition, roughly one third of middle aged men 
and women in the United – States have metabolic syndrome.24 The clinical 
importance of metabolic syndrome is that it encompasses a cluster of 
metabolic risk factors associated with an increased risk for type-2 diabetes 
mellitus and cardiovascular disease. 
 
Most prospective studies have shown that subjects with metabolic 
syndrome are at an increased risk of incident cardiovascular disease26,40 
and mortality due to cardiovascular disease.34,35,48 However, many of these 
studies excluded diabetic patients from their study populations.26,40 
Diabetic patients are at a greater risk for cardiovascular disease than non-
diabetic subjects, and it has been suggested that metabolic syndrome is 
responsible for the increased prevalence of cardiovascular disease seen in 
diabetic patients.3 Therefore it is important to evaluate the association of 
metabolic syndrome according to standard definitions on cardiovascular 
disease in diabetic patients. Knowledge of such an impact of metabolic 
syndrome is essential for developing clinical guidelines for its prevention 
and treatment. 
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AIMS OF THE STUDY 
 
 
 
1. To estimate the prevalence of metabolic syndrome in subjects with 
type-2 diabetes mellitus in a population of South Tamilnadu using 
NCEP – ATP III guidelines. 
 
2. To determine the association of metabolic syndrome with 
cardiovascular (coronary and cerebrovascular) events in these diabetic 
patients. 
 
3. To determine whether modifications of the above said guidelines are 
necessary to identify patients with cardiovascular (coronary and 
cerebrovascular) problems in our population. 
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REVIEW OF LITERATURE 
 
Metabolic syndrome is characterised by a constellation of metabolic 
risk factors in one individual.29,57 The individual components of the 
metabolic syndrome are complex conditions likely to be underpinned by 
multiple genetic and environmental causes. That these risk factors should 
cluster together has been formally confirmed in several large population 
studies, holding the promise that these diverse conditions may in turn 
share genetic or environmental causes.  
 
COMPONENTS OF METABOLIC SYNDROME : 
 
 The National Cholesterol Education Program, Adult Treatment Panel 
III,66 identified 6 components of the metabolic syndrome namely, 
- Abdominal obesity   
- Atherogenic  dyslipidaemia  
- Raised blood pressure  
- Insulin resistance  ±  glucose intolerance  
- Proinflammatory state 
- Prothrombotic state  
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ABDOMINAL OBESITY : 
 Abdominal obesity is the form of obesity most strongly associated with 
the metabolic syndrome. It presents clinically as increased waist 
circumference. Further, it has an adverse effect on cardiovascular risk 
factors such as high blood pressure, high serum cholesterol, low HDL 
cholesterol and hyperglycaemia.  
 
ATHEROGENIC DYSLIPIDEMIA : 
 Atherogenic dyslipidemia manifests in routine lipoprotein analysis by 
raised triglycerides and low concentrations of HDL cholesterol. A more 
detailed analysis might reveal other lipoprotein abnormalities eg., 
increased remnant lipoproteins, elevated apolipoprotein B, small dense  
LDL particles and small HDL particles. All of these abnormalities have 
been implicated as being independently atherogenic. 
 
ELEVATED BLOOD PRESSURE : 
 
 Elevated blood pressure is strongly associated with obesity and 
commonly occurs in insulin resistant persons. Hypertension is listed 
among metabolic risk factors though being multifactorial in origin. 
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INSULIN RESISTANCE : 
 
 Insulin resistance is present in the majority of people with the metabolic 
syndrome. It is strongly associated with other metabolic risk factors and 
correlates univariately with cardiovascular disease. Patients with 
longstanding insulin resistance frequently manifest glucose intolerance. 
When glucose intolerance evolves into diabetes level hyperglycemia, 
elevated glucose constitutes a major, independent risk factor for 
cardiovascular disease. 
 
PROINFLAMMATORY STATE : 
 A proinflammatory state recognized clinically by elevations of                
C–reactive protein (CRP) is commonly present in persons with 
metabolic syndrome. Multiple mechanisms underlie elevations of CRP. 
One cause is obesity, because excess adipose tissue releases 
inflammatory cytokines that may elicit higher CRP levels.  
PROTHROMBOTIC STATE : 
 .A prothrombotic state, characterised by increased plasminogen 
activator inhibitor (PAI-1) and fibrinogen is associated with metabolic 
syndrome. 
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ETIOPATHOGENESIS OF METABOLIC SYNDROME  
 
 The metabolic syndrome has three potential etiological categories.30  
1. Obesity and disorders of adipose tissue 
2. Insulin Resistance 
3. Constellation of independent factors (eg. molecules of hepatic, 
vascular and immunologic  origin)  
 
1. Obesity and Abnormal Body Fat Distribution : 
Adult Treatment Panel III considered the “Obesity epidemic” as 
mainly responsible for the rising prevalence of metabolic syndrome. 
 Obesity contributes to hypertension, high serum cholesterol, low 
HDL cholesterol and hyperglycemia, and it is otherwise associated with 
higher cardiovascular disease risk. Abdominal obesity especially correlates 
with metabolic risk factors. 
 Excess adipose tissue releases several products that apparently 
exacerbate these risk factors. They include non esterified fatty acids 
(NEFA), cytokines, PAI-1 and adiponectin.  A high plasma NEFA level 
overloads muscle and liver with lipid, which enhances insulin resistance. 
High CRP levels accompanying obesity may signify cytokine excess and a 
proinflammatory state. 
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 An elevated PAI – 1 contributes to a prothrombotic state, whereas 
low adiponectin levels that accompany obesity correlate with worsening of 
metabolic risk factors. The strong connection between obesity (especially 
abdominal obesity) and risk factors led Adult Treatment Panel III to define 
the metabolic syndrome essentially as a clustering of metabolic 
complications of obesity. 
 
2. Insulin Resistance : 
A second category of causation is insulin resistance.12,27,41,74 The insulin 
resistance or its accomplice hyperinsulinaemia, is supposed to directly 
cause other metabolic risk factors. But, identifying a unique role for insulin 
resistance in the causation of other risk factors is complicated by the fact 
that it is linked to obesity. 
Though insulin resistance generally rises with increasing body fat 
content, a broad range of insulin sensitivities exist at any given level of 
body fat.1 For eg. most people with categorical obesity (Body mass index 
[BMI] ≥ 30 kg/m2) have post-prandial hyperinsulinaemia and relatively low 
insulin sensitivity, but variation in insulin sensitivities exist even within the 
obese population. 
   Also, in some populations eg. South Asians, insulin resistance occurs 
commonly even with body mass index<25 kg/m2. South Asians and others 
who manifest insulin resistance with only mild-to-moderate overweight can 
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be said to have primary insulin resistance. Even with primary insulin 
resistance, however, weight gain seems to enhance insulin resistance and 
metabolic syndrome. Thus, dissociation of obesity and primary insulin 
resistance in-patients with metabolic syndrome is difficult.  
 
Insulin resistance does play a role in the causation of metabolic 
syndrome. The insulin resistant muscle already overloaded with lipid from 
high plasma NEFA levels, diverts excess NEFA to liver, promoting fatty 
liver and atherogenic dyslipidemia. Hyperinsulinaemia may enhance output 
of very low-density lipoprotein cholesterol, raising triglyceride levels. Insulin 
resistance in muscle predisposes to glucose intolerance, which can be 
worsened by increased hepatic gluconeogenesis in insulin resistant liver. 
Finally, insulin resistance may raise blood pressure by a variety of 
mechanisms.  
 
3. Independent factors that mediate specific components of the 
metabolic syndrome : 
 Beyond obesity and insulin resistance, each risk factor of the 
metabolic syndrome is subject to its own regulation through both genetic 
and acquired factors. This leads to variability in expression of risk factors. 
Lipoprotein metabolism, for instance, is richly modulated by genetic 
variation, hence expression of dyslipidemias in response to obesity and /or 
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insulin resistance varies considerably. Similarly blood pressure is also 
regulated by both genetic and acquired factors. Moreover, glucose levels 
also depend on insulin secretory capacity as well as insulin sensitivity. 
 
CLINICAL DIAGNOSIS OF METABOLIC SYNDROME : 
Many persons seen in clinical practice are readily recognised as 
having multiple metabolic risk factors.     
 Clinical studies have noted a high correlation between abdominal 
obesity and the risk factors characteristic of metabolic syndrome.6,18,19,30,54 
For example, closely associated with abdominal obesity is an elevation of 
serum trigycerides.8,37,49 The elevation can be borderline (150-199 mg/dl) 
or high (>= 200 mg/dl). Similarly, HDL-cholesterol levels <40 mg /dl occur 
commonly in men with insulin resistance39 and marginal reductions of 
HDL-cholesterol levels are observed commonly in women with the 
syndrome.53,69 Thus for women, HDL cholesterol <50 mg/dl, would count 
as one indicator in the diagnosis of metabolic syndrome. A moderately 
strong association also exists between insulin resistance and 
hypertension.44-46 
   
On the other hand, impaired fasting glucose usually is an indicator of 
insulin resistance and is frequently accompanied by other metabolic risk 
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factors,32,68 hence measurement of fasting glucose in overweight and 
obese persons is suggested.       
 
 A portion of persons with impaired fasting glucose will eventually 
develop type 2 diabetes21,47 which further enhances the risk of coronary 
heart disease. Type 2 diabetes mellitus is the epitome of metabolic 
syndrome. Other components of the metabolic syndrome (insulin 
resistance, proinflammatory state and prothrombotic state) cannot be 
identified by routine clinical evaluation. However, in the presence of 
abdominal obesity, they are often present. 
 
ATP III CRITERIA FOR CLINICAL DIAGNOSIS OF METABOLIC 
SYNDROME : 
 
 The National Cholesterol Education Programme (NCEP) expert 
panel on detection, evaluation and treatment of high blood cholesterol in 
adults (Adult Treatment Panel III) has proposed the following clinical 
criteria for identification of metabolic syndrome.  
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ATP III CRITERIA FOR CLINICAL IDENTIFICATION OF  
METABOLIC SYNDROME : 
  
RISK FACTORS DEFINING LEVEL 
Abdominal obesity, given as 
waist circumference  
Men 
Women  
 
 
> 102 Cm (> 40 in) 
> 88 Cm (> 35 in) 
Triglycerides  > 150 mg/ dl 
HDL cholesterol  
Men 
Women  
 
< 40 mg / dl 
< 50 mg / dl 
Blood Pressure  > 130 / > 85 mm Hg  
Fasting Glucose  > 110 mg / dl 
 When 3 of the 5 listed characteristics are present, a diagnosis of 
metabolic syndrome can be made.  
 Cutoff points for several of these are less stringent than usually 
required to identify a categorical risk factor, because multiple marginal risk 
factors can import significantly increased risk for cardiovascular disease.33 
 Overweight and obesity are associated with insulin resistance and 
metabolic syndrome. However the presence of abdominal obesity is more 
highly correlated with metabolic risk factors than is an elevated body mass 
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index. Therefore, the simple measure of waist circumference is 
recommended to identify the body weight component of the metabolic 
syndrome.33  
 The Adult Treatment Panel III panel did not find adequate evidence 
to recommend routine measurement of insulin resistance (eg. plasma 
insulin), proinflammatory state (eg. high sensitivity C-reactive protein), or 
prothrombotic state (eg. fibrinogen or PAI-1) in the diagnosis of metabolic 
syndrome.66  
 Some male patients can develop multiple metabolic risk factors 
when the waist circumference is marginally increased (eg. 94-102 cm) (37 
to 39 inches). Such patients may have a strong genetic contribution to 
insulin resistance. They should benefit from lifestyle changes, similar to 
men with categorical increases in waist circumference.66  
 The presence of type 2 diabetes mellitus does not exclude a 
diagnosis of metabolic syndrome.30 
 
METABOLIC SYNDROME AS A PREDICTOR OF DIABETES : 
 
 The Framingham investigators examined their extensive database 
for the relation between metabolic syndrome and future development of 
both diabetes and cardio vascular disease.30  Their analysis was carried 
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out on 3323 Framingham offspring men and women in  8 years of follow 
up.  
They found out that metabolic syndrome was highly predictive of 
new onset diabetes mellitus and nearly half of the population attributable 
risk for diabetes could be explained by the presence of Adult Treatment 
Panel III criteria for metabolic syndrome. 
 
DIABETES AS A PREDICTOR OF CARDIOVASCULAR DISEASE : 
 Cardiovascular disease is increased in individuals with type-2 
diabetes mellitus. The Framingham study revealed a marked increase in 
peripheral arterial disease, coronary artery disease, myocardial infarction 
and sudden death in subjects with type-2 diabetes mellitus. Type-2 
diabetic patients without a prior myocardial infarction have a similar risk for 
coronary artery related events as non-diabetic individuals who have had a 
prior myocardial infarction.  
 
The increase in cardiovascular morbidity and mortality appears to be 
related to the synergism of hyperglycaemia with other cardiovascular risk 
factors.  
 
 
 15
METABOLIC SYNDROME AS A PREDICTOR OF 
CARDIOVASCULAR DISEASE IN DIABETIC INDIVIDUALS: 
 
 The clinical importance of metabolic syndrome is related to its 
putative impact on cardiovascular morbidity and mortality. 
 Most prospective studies have shown that subjects with metabolic 
syndrome are at an increased risk of incident cardiovascular disease40 and 
mortality due to the same. However, many of these studies excluded 
diabetic patients from their study populations.26,40 Diabetic populations are 
known to be at a greater risk for cardiovascular disease than non-diabetic 
subjects, and it has been suggested that metabolic syndrome is 
responsible for the increased prevalence of coronary heart disease seen in 
diabetic patients.3 Therefore it is important to evaluate the association of 
metabolic syndrome with cardiovascular disease in diabetic subjects using 
the commonly used National Cholesterol Education Programme Adult 
Treatment Panel III guidelines for metabolic syndrome. 
 
MANAGEMENT OF UNDERLYING RISK FACTORS : 
 The underlying risk factors that promote the development of 
metabolic syndrome are overweight and obesity, physical inactivity and an 
atherogenic diet. The current guidelines on the management of individual 
components of the metabolic syndrome emphasize life style modification 
as first line therapy. Adult Treatment Panel III introduced the concept of 
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metabolic syndrome into its cholesterol guidelines in an attempt to highlight 
the need for more intensive life style therapy as a means to prevent 
cardiovascular disease in higher-risk patients. Drug therapy is considered 
secondary.31  
 
OVERWEIGHT AND OBESITY : 
 Abdominal obesity, [defined as waist circumference > 102 cm (40 
inches) in men and >88cm (35 inches) in women] is identified with several 
components of the metabolic syndrome. Adult Treatment Panel III 
recommended that abdominal obesity be considered one of the risk factor 
for metabolic syndrome. Individuals can have metabolic syndrome with a 
lesser degree of or no abdominal obesity if three of the remaining 
components are found.31 
 Obesity guidelines13 stress the need for weight reduction using 
behavioural change to reduce caloric intake and increase  physical activity.  
 For long term weight loss reduced-energy diets, consisting of 
modest 500 to 1000 calorie/ day reduction is effective. The realistic goal for 
weight reduction is to reduce body weight by around seven to ten percent 
over a period of six to twelve months. Long term maintenance of weight 
loss is best achieved when regular exercise is included in the weight-
reduction regimen.  
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 The other factors that should be emphasised include improvements 
in eating habits, social support, stress management and a regular exercise 
regimen. Professional support in the form of nutrition counselling would 
also be helpful.  
PHYSICAL INACTIVITY : 
 Regular exercise and fitness improve several metabolic risk factors 
and are associated with a reduction in the risk of developing many chronic 
diseases.57 Hence physical inactivity is considered to be an important 
contributor to the development of metabolic syndrome.  
The current physical activity guidelines2,16,67 recommend practical, 
regular and moderate regimens for exercise. The standard exercise 
recommendation is a daily minimum of thirty to forty five minutes of 
moderate intensity physical activity. The entire duration of physical activity 
should include a warm up phase of five to ten minutes, aerobic phase of 
twenty to thirty minutes and cool down phase of 5 to 10 minutes at the end. 
Increasing the level of physical activity enhances the beneficial effect.  
Incorporating multiple short (10 to 15 minutes) bouts of activity (brisk 
walking), avoiding common sedentary activities in leisure time (television 
watching), adding regular exercise into daily schedule (eg. brisk walking, 
jogging, team sports) and self monitoring of exercise are some of the 
recommendations for physical activity.   
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 Physical inactivity and metabolic syndrome are closely interrelated. 
Hence management of metabolic syndrome should include initiation of a 
program of regular physical activity. Physical activity is one modality 
associated with successful weight reduction. The combination of weight 
reduction program with increased physical activity can halve the 
progression to new-onset diabetes over a period of several years in 
persons with prediabetes which is defined as impaired fasting glucose 
(IFG) or impaired glucose tolerance (IGT).31 
 The favourable effect of weight reduction and exercise on 
cardiovascular disease risk factors provides strong support and justification 
for recommending them as part of a regimen to reduce risk for the same.  
 
DIETARY MODIFICATION : 
 
 Adult Treatment Panel III recommendations for diet composition of 
patients with metabolic syndrome include low intake of saturated fats and 
cholesterol; reduced consumption of simple sugar and increased intake of 
fruits, vegetables and whole grains.4,31,42 The clinical significance of diet 
induced atherogenic dyslipidemia is undetermined. 
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 Recent small clinical trials indicate that improvement of atherogenic 
dyslipidemia by increasing unsaturated fat consumption is relatively small 
when compared with standard dietary recommendations.4,42 
 
MEDICAL MANAGEMENT OF METABOLIC RISK FACTORS : 
 Therapeutic life style modification is the first line therapy for 
metabolic syndrome, though drug therapy may be necessary in many 
patients to achieve the recommended goals.  
 
ATHEROGENIC DYSLIPIDEMIA : 
 HMGCo-A reductase inhibitors reduce all apolipoprotein B 
containing lipoproteins and can achieve the ATP III goals for LDL 
cholesterol as well as for non HDL cholesterol.3 
 Fibrates improve all components of atherogenic dyslipidemia and 
also appears to reduce the risk for cardiovascular disease.  
 Fibrates in combination with statins is effective, though the risk of 
myopathy is increased.55 
 Fenofibrate does not interact adversely with statin catabolism and 
thus may be safe to use in combination therapy. 
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 Nicotinic acid has similar features to fibrates and the combination of 
nicotinic acid and statins is promising. Nicotinic acid is supposed to be 
effective in raising HDL cholesterol levels, but higher doses may raise 
plasma glucose levels.  
 
ELEVATED BLOOD PRESSURE : 
 Blood pressure > 130 / > 85 mm Hg is one of the risk factor defining 
levels in metabolic syndrome. In-patients with categorical hypertension 
(blood pressure > 140 / > 90 mm Hg) drug therapies are required 
according to Joint National Committee 714 recommendations. In patients 
with established diabetes mellitus, antihypertensives should be introduced 
at even lower blood pressures  ( > 130 / > 80 mm Hg) 
 No class of antihypertensive drug has been identified as being 
uniquely efficacious in patients with metabolic syndrome.  
 
INSULIN RESISTANCE AND HYPERGLYCAEMIA : 
 There is a possibility in that, the drugs that reduce insulin resistance 
will delay onset of type-2 diabetes mellitus and reduce the cardiovascular 
risk when metabolic syndrome is present. The diabetes prevention 
program showed that metformin therapy in patients with prediabetes will 
prevent or delay the development of diabetes.31  
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          Troglitazone had also been suggested with a similar effect  
but has been withdrawn from commercial use.  
           Insulin resistance is associated with an increased cardiovascular 
disease risk, but neither metformin nor thiazolidinediones have been 
shown to reduce the risk in those persons with metabolic syndrome, 
prediabetes or diabetes. Thus there is insufficient evidence to recommend 
these drugs for anything other than their glucose – lowering action.  
 The presence of metabolic syndrome in patients with type 2 diabetes 
mellitus conveys a particularly high risk for cardiovascular disease. When 
both are present appropriate treatment of dyslipidemia and hypertension is 
essential. Good glycaemic control is also essential as it will reduce 
cardiovascular disease events. Choice of drug therapy to achieve 
glycaemic control is based on clinical judgement.31 
 
 
PROINFLAMMATORY STATE : 
 Proinflammatory state is characterised by elevated cytokines                
(eg. tumor necrosis factor - ∝ and interleukin – 6) as well as by elevations 
in acute phase reactants (CRP and fibrinogen). Measurement of CRP (C-
reactive protein) is the most practical way to assess the presence of an 
inflammatory state CRP levels tend to be higher than normal level in 
patients with metabolic syndrome.31 
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 An elevated CRP ( > 3 mg / 1ml ) is an emerging risk factor for 
cardiovascular disease. American Heart Association and Centre for 
Disease Control (CDC) have issued guidelines for the measurement of 
CRP in clinical practice. The testing should be limited to individuals 
assessed to be at an intermediate risk by Framingham scoring. The 
purpose of determining CRP levels in an intermediate risk patient is to find 
out those with higher CRP levels so that they may be placed in a higher 
risk category.31      
 The practical consequences of elevating the risk category would be 
to intensify life style therapies and make certain that low dose aspirin is 
used. 
 
PROTHROMBOTIC STATE : 
 The prothrombotic state in patients with metabolic syndrome is 
characterised by elevations of fibrinogen, plasminogen activator inhibitor - 
1 and possibly other coagulation factors.  These factors are not measured 
routinely in clinical practice.  
 The risk for thrombotic events can be reduced by aspirin therapy. 
The American Heart Association currently recommends use of aspirin 
prophylaxis in most patients whose 10 year risk for coronary heart disease 
is > 10% as determined by Framingham risk scoring.31 
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 Including patients with metabolic syndrome when their 10 year risk 
for coronary heart disease is < 10% is appropriate.  
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MATERIALS AND METHODS 
 
 The study was conducted on all patients attending the diabetic clinic 
at Government Tirunelveli Medical College Hospital during the year 2005. 
This is an observational clinical study. It was done prospectively. It was a 
one point in time study.  
 
The study population consisted of all patients with type-2 diabetes 
mellitus diagnosed according to the WHO-criteria.70 Patients taking anti-
diabetic and anti-hypertensive agents were also included in the study. 
Gestational diabetics and patients with chronic renal failure were not 
included in the study. A total of 110 patients were screened, 10 patients 
were excluded, seven of them were type 1 diabetics and three suffered 
from chronic renal failure. 
 
 A detailed proforma was prepared which included details regarding 
food habits, literacy status, occupation, annual income and clinical features 
at the time of presentation. 
 
 Weight in kilograms (measured in light clothing without 
shoes/slippers), height, body mass index (BMI) defined as weight in kg by 
square of the height in metres,25 waist circumference was calculated as the 
average of two measurements taken after inspiration and expiration at the 
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midpoint between the lowest rib and iliac crest,43 hip circumference was 
measured at the level of greater trochanter43 and waist hip ratio was 
calculated. Two blood pressure recordings were obtained from the right 
arm of patients in a sitting posture after 10 minutes of rest at 5 minutes 
intervals and their mean value was calculated. Blood pressure was also 
recorded in the standing posture. 
 
Biochemical variables : 
 
 Venous blood was drawn after an overnight fast and before the 
administration of any antidiabetic medications25. 
 
Biochemical Methods : 
 
 Measurement of lipid profile and glucose were made with Transasia 
ERBA XL-300 auto analyser.  
 
The National Cholesterol Education Program, Adult Treatment Panel 
III criteria for diagnosis of metabolic syndrome was used in all patients. 
Cardiovascular end points included either coronary or cerebrovascular 
events. Coronary end points were defined as those experiencing typical 
chest pain or having a previous history of myocardial infarction as 
validated by changes in a 12-lead electrocardiogram. Cerebrovascular end 
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points included stroke and transient ischaemic attacks. Stroke events were 
defined as a constellation of focal or global neurologic deficits of sudden or 
rapid onset and for which there was no apparent cause other than a 
vascular accident,62 as determined by history and neurological 
examination. 
  
                However there were certain limitations to the study, wherein 
coronary heart disease was diagnosed only on the basis of history, 
physical examination and electrocardiogram and not on the basis of 
coronary angiography. This is expected to decrease the sensitivity of 
detecting coronary heart disease. Cerebrovascular involvement was 
similarly studied on the basis of detailed history and physical examination 
only. It is understood that they are only a subjective assessment, though 
they were done in great detail. Cerebrovascular involvement was similarly 
studied on the basis of detailed history and physical examination only. It is 
understood that they are only a subjective assessment, though they were 
done in great detail.  
 
Statistical Analysis : 
 
 The results are inferred on the basis of statistical tools viz. ‘Z’ test, 
students ‘t’ test, association of attributes (Q) and odd’s ratio (O.R.) for 
attributable risk. 
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OBSERVATION AND RESULTS 
 
The study was done on patients attending diabetic clinic at 
Government Tirunelveli Medical College, Hospital. The study was a 
prospective one. A total of 100 patients were selected as study subjects. 
 Out of the 100 cases, 62 were males and  38 were females. 
Table 1 : Age and sex-wise distribution of subjects 
Age group Male Female Total 
30 – 39 1 2 3 
40 – 49 15 6 21 
50 – 59 26 14 40 
60 – 69 14 13 27 
70 – 79 6 3 9 
Total 62 38 100 
Mean 56.5 57.4 56.8 
S.D. 9.5 9.8 9.6 
 Z = 0.452 ; p > 0.05 
      Table 1 illustrates the age and sex-wise distribution of the study 
subjects. The mean age of the male subjects were 56.5 ± 9.5 and the 
mean age of the female subjects were 57.4 ± 9.8. The mean age of the 
study population is 56.8 ± 9.6. The mean ages of the male and female sub-
groups were comparable and the difference is not statistically significant 
(p>0.05). 
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Table 2 : Age, sex and metabolic syndrome wise distribution 
Male Female Total 
 
Age group 
M.S. + M.S. - M.S. + M.S. - M.S. + M.S. - 
30 – 39 0 1 1 1 1 2 
40 – 49 9 6 3 3 12 9 
50 – 59 14 12 6 8 20 20 
60 – 69 6 8 10 3 16 11 
70 – 79 4 2 3 0 7 2 
Total 33 29 23 15 56 44 
Mean 55.3 56.4 59.8 53.7 57.9 55.5 
S.D. 9.7 9.4 10.2 8.1 9.9 10.9 
Significance Z = 0.45    p > 0.05 Z = 2.0   p < 0.05 Z = 1.13    p > 0.05 
 
Table 2 explains the age and sex-wise distribution of cases with and 
without metabolic syndrome. 
 
 
In the male subgroup the mean age of cases with metabolic 
syndrome is 55.3 ± 9.7 and the mean age of cases without metabolic 
syndrome is 56.4 ± 9.4. The mean ages of cases with and without 
metabolic syndrome were compared and the difference is not statistically 
significant (p > 0.05). 
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 In the female sub-group the mean age of cases with metabolic 
syndrome is 59.8 ± 10.2 and the mean age of cases without metabolic 
syndrome is 53.7 ± 8.1. The difference between the mean ages of the 
above group is statistically significant, ( p < 0.05)   
 
The prevalence of metabolic syndrome among males is 53.2% and 
among females is 60.5%. The difference is not statistically significant 
(p>0.05). The total prevalence of metabolic syndrome among subjects with 
type-2 diabetes mellitus is 56%. 
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Table 3 :  Male subjects classified according to the presence and  
absence of metabolic syndrome and cardiovascular  
disease.  
 
M.S. + M.S. - Total 
 
Age group 
CVD + CVD - CVD + CVD - CVD + CVD - 
30 – 39 0 0 1 - 1 - 
40 – 49 1 8 2 4 3 12 
50 – 59 4 10 7 5 11 15 
60 – 69 4 2 4 4 8 6 
70 – 79 1 3 0 2 1 5 
Total 10 23 14 15 24 38 
Mean 60.0 55.0 55.0 57.7 57.1 56.1 
S.D. 8.1 9.8 7.6 10.0 8.7 9.9 
Significance t = 1.29    p > 0.05 t = 0.73  p > 0.05 z = 0.02    p > 0.05 
 
 
Among males, age group wise presence and absence of 
cardiovascular disease in subjects with and without metabolic syndrome 
are shown in Table 3. 
 
The mean age of male subjects with metabolic syndrome and 
cardiovascular disease was 60.0 ± 8.1 and the mean age of male subjects 
with metabolic syndrome and without cardiovascular disease was 55 ± 9.8. 
The observed difference between the mean age of the male and female 
subjects is statistically insignificant (p>0.05). 
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Similarly, among male subjects without metabolic syndrome, the 
mean age of subjects with cardiovascular disease was 55 ± 7.6 and the 
mean age of subjects without cardiovascular disease was 57.7±7.6 and 
the difference in the mean ages is statistically insignificant (p>0.05). 
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Table 4 :  Female subjects classified according to the presence  
and absence of metabolic syndrome and  
cardiovascular disease.  
M.S. + M.S. - Total 
 
Age group 
CVD + CVD - CVD + CVD - CVD + CVD - 
30 – 39 0 1 1 0 1 1 
40 – 49 1 2 1 2 2 4 
50 – 59 3 3 3 5 6 8 
60 – 69 6 4 1 2 7 6 
70 – 79 2 1 0 0 2 1 
Total 12 11 6 9 18 20 
Mean 62.5 56.8 51.7 55.0 61.2 56.5 
S.D. 8.3 11.1 9.4 6.6 10 9.4 
Significance t = 1.72 ; p > 0.05 t = 0.71 ; p > 0.05 t = 1.33 ; p > 0.05 
        
Female subjects classified age-wise according to the presence or 
absence of metabolic syndrome and cardiovascular disease, are displayed 
in Table 4. 
 
The mean age of female subjects with metabolic syndrome and 
cardiovascular disease is 62.5 ± 8.3. The mean age of female subjects 
with metabolic syndrome and without cardiovascular disease is 56.8 ± 
11.1. The difference between the mean ages is statistically insignificant 
(p>0.05) 
 36
 
 
In subjects without metabolic syndrome, the difference between the 
mean ages of cases with cardiovascular disease (51.7±9.4) and without 
cardiovascular disease (55±6.6) is statistically insignificant (p>0.05). 
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Table 5 :  Percentage distribution of sex wise cardiovascular 
disease (CVD) cases with and without metabolic  
syndrome (MS) 
 
Sex % of CVD with MS % of CVD 
without MS 
Significance 
Male 30.3 (10) 48.3 (14) p > 0.05 
Female 52.2 (12) 40.0 (6) p > 0.05 
TOTAL 39.3 (22) 45.5 (20) p > 0.05 
 
      Table 5 shows the percentage wise distribution of cardiovascular 
disease in subjects with and without metabolic syndrome. Sex wise 
prevalence was also assessed. 
 
When compared the observed differences in the percentage 
distribution of cardiovascular disease cases with and without metabolic 
syndrome were statistically insignificant (p>0.05) 
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Table 6 :  Comparison of mean ages of cardiovascular disease 
cases with and without metabolic  syndrome  in male subjects 
 
MALE 
CVD + 
 
MS + MS - 
Mean 60.0 55.0 
S.D. 8.1 7.6 
η 10 14 
SIGNIFICANCE t = 1.39          ;       p > 0.05 
 
     
Table 6, shows the mean ages of male cardiovascular disease 
subjects with and without metabolic syndrome. 
 
The mean age of those with metabolic syndrome is 60.0 ± 8.1 and 
the mean age of those without metabolic syndrome is 55.0 ± 7.6. 
       
 Eventhough there is an observed difference of 5 years, this 
difference is not statistically significant (p>0.05). Hence, age does not play 
any role in the occurrence of cardiovascular disease in male subjects with 
and without metabolic syndrome. 
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Table 7 :  Comparison of mean ages of cardiovascular disease 
cases in female subjects with and without metabolic 
syndrome  
 
FEMALE 
CVD + 
 
MS + MS - 
Mean 62.5 51.7 
S.D. 8.3 9.4 
η 12 6 
Significance     t = 2.23               ;             p < 0.05 
 
        
The mean ages of female cardiovascular disease subjects with and 
without metabolic syndrome are displayed in Table 7. 
 
The mean age of female cardiovascular disease subjects with 
metabolic syndrome is 62.5 ± 8.3 and the mean age of those without 
metabolic syndrome is 51.7 ± 9.4. 
 
The observed difference is nearly ten years and the difference is 
statistically significant (p<0.05). 
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Fig.6. Comparison of mean ages of 
cardiovascular disease cases with and 
without metabolic syndrome in female 
subjects
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Table 8 :  Association of male cardiovascular disease cases with  
and without metabolic syndrome 
 
 M.S.+ M.S.- 
CVD + 10 (30.3%) 14 (48.3%) 
CVD - 23 (69.7%) 15 (51.7%) 
 Q = - 0.364    ;    O.R. = 0.466 
 
 Table 8 illustrates the association of cardiovascular disease in 
subjects with and without metabolic syndrome among males. 
 
 Among 33 male metabolic syndrome subjects, cardiovascular 
disease was present in 10 (30.3%) and not present in the remaining 23 
(69.7%) subjects. Out of the 29 subjects without metabolic syndrome 14 
subjects (48.3%) had cardiovascular disease and the remaining 15 
(51.7%) subjects were not found to have cardiovascular disease. 
 
 The risk of association of metabolic syndrome with cardiovascular 
disease is very low (O.R. = 0.466). 
  
 Hence, it can be inferred that metabolic syndrome does not play a 
very important role in predicting cardiovascular disease in males. 
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Fig.7. Association of male cardiovascular 
disease cases with and without 
metabolic syndrome
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Table 9 :  Association of female cardiovascular disease cases  
with and without metabolic syndrome 
 
 M.S.+ M.S.- 
CVD + 12 (52.2%) 6 (40%) 
CVD - 11 (47.8%) 9 (60%) 
 Q = 0.241     ;       O.R. = 1.6 
 
Association of cardiovascular disease in female subjects with and 
without metabolic syndrome is explained in Table 9. 
 
Among 23 female subjects with metabolic syndrome 12 (52.2%) had 
cardiovascular disease, while 11 (47.8%) did not suffer from the same. In 
female subjects without metabolic syndrome, cardiovascular disease was 
present in 6 (40%) while it was absent in 9 (60%). 
 
The risk of association of metabolic syndrome with cardiovascular 
disease is high in females (Odds Ratio =1.6)  
 
 Hence, metabolic syndrome is found to be useful in predicting 
cardiovascular disease in female patients. 
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Table 10 :  Association of cardiovascular disease with 
blood pressure in male and female subjects 
 
 MALE FEMALE 
 ≥ 130 / 85 < 130 / 85 ≥ 130 / 85 < 130 / 85 
CVD + 17 7 15 3 
CVD - 24 14 8 12 
 Q = 0.1724 ;  O.R. = 1.35 Q = 0.764    ;   O.R. = 7.5 
      
The association between cardiovascular disease and blood pressure 
of male and female subjects are furnished in the above table. 
As seen in Table 10, there is an association within the male 
population between elevated blood pressure and cardiovascular disease. 
The risk of elevated blood pressure is 1.35 times. Similarly, among the 
female population, elevated blood pressure is highly associated with 
cardiovascular disease (O.R.=7.5). 
The mean elevated systolic blood pressure (≥ 130mmHg) in males is 
142.4 ± 13.6 and 155 ± 23.1 in females. The difference of mean elevated 
systolic blood pressure is statistically significant (p < 0.05). 
The mean elevated diastolic blood pressure (≥ 85 mmHg) in males is 
94.4 ± 7.1 and in females is 96.6 ± 9.0. The difference is not statistically 
significant (p>0.05). 
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Fig.9.b. Percentage association of cardiovascular disease with 
blood pressure (Females)
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Table 11 :  Association of cardiovascular disease with waist  
circumference in male and female subjects 
 
 MALE FEMALE 
 > 102 cm < 102 cm > 88 cm < 88 cm 
CVD + 2 22 11 7 
CVD - 4 34 7 13 
 Q = - 0.128 ; O.R. = 0.77 Q = 0.489 ; O.R. = 2.92 
 
        
The association of cardiovascular disease with waist circumference 
in male and female subjects is explained in Table 11.  
 
In respect of increased waist circumference among the male 
population, there is no association with cardiovascular disease. The risk of 
increased waist circumference is very less (Odds Ratio = 0.77). Among 
females, there is an association of increased waist circumference with 
cardiovascular disease. The risk of increased waist circumference is 2.92 
times. 
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Fig.10.a. Percentage association of cardiovascular disease with 
waist circumference (Males)
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Fig.10.b. Percentage association of cardiovascular disease with 
waist circumference (Females)
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Table 12 :  Association of cardiovascular disease with  
triglycerides in male and female subjects 
 
 MALE FEMALE 
 ≥ 150 < 150 ≥ 150 < 150 
CVD + 9 17 12 6 
CVD - 20 18 11 9 
 Q = - 0.354   ;   O.R. = 0.476 Q = 0.241   ;   O.R. = 1.6 
 
        
In Table 12, details of association between cardiovascular disease 
and triglyceride levels among male and female subjects are presented. 
 
As seen in Table 12, there is no association of elevated triglyceride 
levels with cardiovascular disease in male subjects. The risk is less (Odds 
Ratio 0.476). 
 
In female subjects there is an association of elevated triglyceride 
levels with cardiovascular disease. The risk of elevated triglyceride level is 
1.6 times. 
 
The mean elevated triglyceride level (>150) is 223.3 ± 76 for males 
and 251.1 ± 96.5 for females and the difference is not statistically 
significant (p > 0.05).   
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Fig.11.a. Percentage association of cardiovascular disease with 
triglyceride levels (Males)
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Fig.11.b. Percentage association of cardiovascular disease with 
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Table 13 :  Association of cardiovascular disease with HDL  
  cholesterol levels in male and female subjects 
 
 MALE FEMALE 
 < 40 > 40 < 50 > 50 
CVD + 13 11 11 7 
CVD - 21 17 15 5 
 Q = - 0.3125  ;  O.R. = 0.52 Q = 0.3     ;  O.R. = 0.5 
 
        
HDL cholesterol levels in male and female subjects and their 
association with cardiovascular disease is given in Table 13. 
 
In both male and female subgroups there is no association of low 
HDL levels with cardiovascular disease (Table 13). The risk of low HDL 
levels is very less (Males : Odds Ratio = 0.52 and Females : Odds Ratio = 
0.5) 
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Fig.12.a. Percentage association of cardiovascular disease with 
HDL cholesterol  levels (Males)
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Fig.12.b. Percentage association of cardiovascular disease with 
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DISCUSSION 
The current study aimed at finding out the prevalence of metabolic 
syndrome in subjects with type-2 diabetes mellitus in a population of South 
Tamilnadu, estimated it to be around 56% based on the NCEP-ATP III 
guidelines. This is much lower than the prevalence estimated by western 
workers in the western population where it was in the range of 80 to 
85%.9,10,25 
However, Chee-Eng-Tan et al found the prevalence of metabolic 
syndrome in subjects with type-2 diabetes mellitus to be around 58% only, 
when they applied NCEP-ATP III guidelines as such without any 
modifications to an Asian population65. Also, ethnic differences were found 
to exist between different populations across Asia. Chee-Eng-Tan et al 
further add that NCEP-ATP III definition of metabolic syndrome when 
applied to an asian population would not only underestimate the 
prevalence of metabolic syndrome but, fail to identify many individuals at 
risk of future cardiovascular disease. This study also observed that there 
were no sex related differences in the prevalence of metabolic syndrome.  
The clinical importance of metabolic syndrome is related to its 
putative impact on cardiovascular disease morbidity. In this study the risk 
of association of cardiovascular disease with metabolic syndrome in male 
subjects was low (O.R.=0.466 and Q= - 0.364) while the risk of association 
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of metabolic syndrome with cardiovascular disease in female subjects was 
almost 1.6 times higher. 
The lack of association of metabolic syndrome with cardiovascular 
disease in males in this study could be due to the higher fixed criteria for 
waist circumference in ATP III guidelines. 
 
The waist circumference criterion probably needs to be reduced to 
make it a more sensitive predictor of risk association. Sone H et al when 
after using the modified version of ATP III guidelines with adjusted waist 
circumference found NCEP definition to be only somewhat predictive of 
cardiovascular disease in males62. 
On analysing the individual components of metabolic syndrome with 
the risk of cardiovascular disease in males it was observed that only one of 
the components namely hypertension was associated to a significant 
extent (O.R.=1.35 and Q=0.1724). The other components namely central 
obesity and dyslipidemia were not associated with cardiovascular disease 
risk in males. 
 
The risk of association of metabolic syndrome with cardiovascular 
disease in females was high (O.R.=1.6 and Q=0.241). However, the mean 
age of females with metabolic syndrome than those without were higher 
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and hence age could possibly be a confounding variable for such an 
association. 
While analysing cardiovascular risk in relation to the different 
components of metabolic syndrome in females, it was observed that 
hypertension, central obesity and hypertriglyceridaemia were associated 
with a higher risk in female subjects. Among these the most significant 
association was between hypertension and metabolic syndrome in 
females, the risk being 7.5 times higher. 
 
Further, hypertension was the only individual component 
consistently associated with risk of cardiovascular disease in both male 
and female subjects. Similar observations have been made in the Bruneck 
study10 which aimed at prospectively evaluating the risk of cardiovascular 
disease in the form of progressive carotid atherosclerosis and incident 
coronary heart disease in subjects with metabolic syndrome. They found 
that hypertension was the only significant independent predictor of incident 
coronary heart disease, the risk being 3.1 times more. 
 
Finally, it can be said that the use of NCEP-ATP III guidelines in its 
present form without suitable modifications for our population would largely 
underestimate the population at risk. 
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CONCLUSION 
 
The prevalence of metabolic syndrome in subjects with type-2 
diabetes mellitus in this study is 56%. The prevalence is comparable with 
studies conducted in the asian population but less than that in the western 
population. 
 
Among females, the risk of cardiovascular disease is high (O.R.=1:6 
and Q=0.241) in subjects with metabolic syndrome. These females 
however belong to a higher age group and age was possibly a 
confounding factor. 
 
In the male subjects there is no significant association of 
cardiovascular disease with metabolic syndrome (O.R.=0.466 and Q = -
0.364). 
 
Systemic Hypertension was the most important individual 
component of the metabolic syndrome that was associated with an 
increased risk of cardiovascular disease [(Males: Q=0.1724; OR = 1.35) 
and  (Females : Q=0.764; O.R. = 7.5)] in both sexes. 
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Dyslipidemia as per the current recommendations of the NCEP ATP 
III guidelines was not significantly associated with cardiovascular disease. 
 
Central obesity measured by waist circumference was not predictive 
of cardiovascular disease among males. (O.R.=0.77 and Q=-0.128) 
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SUMMARY 
 The prevalence of metabolic syndrome in subjects with type-2 
diabetes mellitus is high at 56%, but much less than that in the western 
population. The NCEP ATP III guidelines were somewhat predictive of 
cardiovascular disease only in female patients. These female subjects 
however belong to a higher age group and age was possibly a 
confounding factor. Hypertension was the only individual component that 
had a predictive association with cardiovascular disease in both sexes. 
 
 Hence, in conclusion it could be said that the NCEP ATP III guideline 
definition of metabolic syndrome may need to be modified suitably to 
clearly identify the cardiovascular end points among the diabetic patients in 
a semi-urban population of South Tamilnadu. 
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ANNEXURE - I 
 
PROFORMA 
 
METABOLIC SYNDROME IN SUBJECTS  WITH TYPE 2 DIABETES MELLITUS 
 
NAME    : 
AGE    : 
SEX    : 
HOSPITAL No.   : 
VEGETARIAN   NON VEGETARIAN 
LITERACY 
 ILLITERATE 
 SCHOOL 
 COLLEGE 
OCCUPATION   : 
ANNUAL INCOME  : 
ADDRESS   : 
 
CLINICAL FEATURES AT THE TIME OF PRESENTATION : 
 
POLYURIA 
POLYDYPSIA 
POLYPHAGIA 
WEIGHT LOSS 
UNEXPLAINED FATIGUE 
DELAYED WOUND HEALING 
LEG ULCERS 
TINGLING (OR) NUMBNESS IN EXTREMITIES 
PRURITUS VULVAE 
VISUAL DISTURBANCES 
CHEST PAIN 
BREATHLESSNESS 
OTHERS (MENTION) 
PERSONAL HISTORY : 
SMOKING 
ALCOHOL 
FAMILY HISTORY : 
DIABETES MELLITUS 
HYPERTENSION 
ISCHAEMIC HEART DISEASE 
DYSLIPIDEMIA 
DRUG THERAPY 
STEROIDS 
β - BLOCKERS 
 
OTHERS (MENTION) 
ON EXAMINATION : 
 
CONSCIOUSNESS 
ORIENTATION 
TEMPERATURE 
PALLOR 
CLUBBING 
CYANOSIS 
PEDAL EDEMA 
LYMPHADENOPATHY 
 
PULSE 
 
RATE 
RHYTHM 
PERIPHERAL PULSES 
 
BLOOD PRESSURE 
SITTING (MEAN) 
STANDING 
 
HEIGHT 
WEIGHT 
 BODY – MASS / INDEX 
 
WAIST CIRCUMFERENCE 
HIP CIRCUMFERENCE 
 WAIST – HIP RATIO 
 
CARDIOVASCULAR SYSTEM 
 
 FIRST HEART SOUND 
 SECOND HEART SOUND 
ADDED SOUNDS / MURMUR 
 
RESPIRATORY SYSTEM :  
 BREATH SOUNDS  : 
 ADDED SOUNDS : 
 
CNS : 
 FOCAL NEUROLOGICAL DEFICIT (MENTION) 
 VIBRATION TEST 
 RHOMBERG’S 
SKIN 
FOOT 
 
INVESTIGATIONS : 
BLOOD SUGAR 
 RANDOM 
 FASTING 
 POST-PRANDIAL 
 
LIPID PROFILE   
 
BLOOD UREA 
SERUM CREATININE 
 
ECG 
 
URINE  ALBUMIN 
  SUGAR 
  DEPOSITS 
 
 
 
ANNEXURE - II 
 
MASTER CHART 
BS 
 
Metabolic 
Syndrome   
CVD S. 
No 
Name / 
Hospital No 
Age Sex Food 
H
abit 
L
iteracy 
Occupation  Incom
e 
C
linical Feature 
A
t Presentation 
Fam
ily H
istory 
 
 
S    A 
D
r
u
g 
   
T
r
e
a
t
m
e
n
t  
B
lood Pressure  
Ht 
(cm)  
Wt
(kg) 
BMI  WC HC  WHR LIPID 
TGL  HDL
R       F 
+    - 
ECG TIA 
 /  
CVA 
+ - 
1. Jesudasan  
(56619) 
48 M NV C Teacher  1,00,000 Polyuria DM 
(M) 
-     - - 140/ 90 149 54 24. 32 91 95 0.95 209     22 224      112 +  WNL   - 
2. Sivan 
(46316) 
47 M NV S Farmer 5000 Leg ulcer      - -    + - 150/100 160 70 27. 34 102 100 1.02 160      54 250       134 +  WNL   - 
3. Backiyathai  
(45128) 
60 F NV IL Housewife  12000 Giddiness       - -      - - 150/ 90 155 68 28. 30 115 112 1.02 141      42 334      225 +  WNL   - 
4. Udhuman 
Muhaideen 
(47793) 
55 M NV C P.W.D 1,20,000Numbness in
Extremities
DM(F) -     - - 150/ 90 163 70 26.34 98 102 0.96 89        50 346       211 +  WNL   - 
5. Pathimuthu 
(44751) 
50 F NV IL Housewife  24,000 Giddiness DM 
(M) 
HT 
(M) 
-    - - 160/ 90 145 62 29.48 102 98 1.04 156     28 213      112 +  WNL    - 
6. Chelladurai  
(47127)  
61 M NV S Salesman  35,000Unexplained
Fatigue 
- -    - - 140 /90 155 53 22. 06 88 90 0. 97 123      34 220         94 +  Inferolateral 
wall Ischaemia  
+  
  7. Badhar Nisha 
(454/05) 
60 F NV IL Housewife  10,000 Giddiness - -     - - 120/ 90 141 70 35. 21 100 108 0. 92 354      62 247       171 +  OLD 
IWMI 
 +  
  8. Joseph 
 (452 / 05)  
55 M NV S Factory 
Worker  
12,000 Polyuria - +   + - 110/ 80 165 70 25. 71 92 104 0. 88 199      56 294        235  _ Antero lateral 
Ischaemia 
+  
  9. Pappa 
(453/05)  
45 F NV IL Cottage  
Industry  
2,400 Protracted
Vomiting
- -     - - 140/ 90 147 50 23. 13 80 95 0. 84 344     46 348       265 +  WNL   - 
10. Abul Hassan 
(450/ 05 ) 
59 M NV S Madrasa  15,000 Polyuria DM(F) -     - - 140 / 80 155 68 28.30 94 102 0.92 193     72 410       326 +  WNL    - 
11. Velammal 
(42897)  
35 F NV S Housewife  36, 000Unexplained
fatigue 
DM 
( F) 
-     - - 130/ 80 152 67 28. 99 96 108 0. 88 156     70 328        286 +  WNL   - 
12. C. Subbiah  
 (445 / 05)  
72 M V S B.D.O 60,000 Giddiness - -     - - 140 / 80 166 79 28. 67 101 104 0. 97 150     38 233       174 +  WNL   - 
13. N. Subbiah  
(42884) 
49 M NV S Bus 
Conductor  
40,000 Multiple 
Sebaceous 
cyst 
- -     - - 110/ 80 170 48 16. 60 99 96 1. 03 339       60 208      238  - WNL   - 
14. Poovalingam  
(47110) 
55 M NV S Carpenter  12,000 Visual  
distur 
bances 
- -     - - 170/ 90 152 52 22. 50 77 86 0. 89 167      34 308      153 +  WNL    - 
15. Gomathi -
ammal  
(446/05) 
65 F NV IL  Coolie  10,000 Asympto 
matic 
- -     - - 160/ 80 147 54 24.99 86 96 0.91 370      48 293      169 +  WNL   - 
16. Neelakandan 
(585/05) 
49 M NV S Farmer  12,000 Polyuria - +    - - 130/ 90 170 76 26. 29 101 100 1. 01 148      38 287      183 +  WNL    - 
17. Duraipandi  
(42904) 
60 M NV IL Farmer  10,000 Delayed 
wound 
healing 
- -    + - 140/ 90 161 61 23. 53 86 98 0. 87 199      38 453      151 +  Old 
ASMI 
 +  
18. Jeyam 
Ponnusamy  
(42593) 
 
53 
 
M 
 
NV 
 
S 
Revenue  
Inspector  
1,00,000 Tingling  in
Extremities
- -     - - 120/ 60 158 64 25. 63 91 94 0. 96 146       44 118*     99*  - WNL   - 
19. Paramasivan  
(42905) 
70 M V S Cycle shop  6,000 Burning 
Micturition
- +    - - 150/ 90 166 63 22. 86  88 91 0. 96 92         32 229       115 +  Inferior wall 
Ischaemia  
+  
20. Chellammal  
(42875) 
68 F V S Housewife  6000 Polyuria DM
(D) 
-     - - 130/ 80 158 48 19. 22 65 72 0. 90 152       54 395       134  - WNL   - 
21. Sundari 
-ammal  
(41926) 
60 F NV S Housewife  18,000Unexplained
Pruritus 
- -     - - 180/110 151 47 20.61 71 88 0.80 331       40  298      200 +  Old ASMI 
 
+ 
 
 
22. Thangabai  
(42416) 
32 F NV S Housewife  10,000 Polydypsia DM
(F) 
-     - - 200/100 148 46 21 81 84 0. 96 129       56 310    177  - Anterior wall 
Ischaemia 
+  
23. Chandra 
sekar  
(42423) 
55 M NV S Cycle  
rickshaw 
man 
6000 Balano 
posthitis 
- +   + - 80 /60 171 54 18. 46 71 83 0. 85 155       20 411    342 +  WNL   - 
24. Rajammal  
(55472) 
70 F NV IL Housewife  12,000 Giddiness - -     - - 220/  
110 
139 60 31. 05 97 108 0.89 112       54 239    145 +  Antero 
lateral 
ischaemia 
+  
25. Lourd Mary 
Williams  
(55741) 
66 F NV C Teacher  72,000 Giddiness DM
(F) 
-     - - 160/90 145 63 29. 96 99 101 0.98 266        32 264    123 +  Old ASMI +  
26. Chandra 
sekhar  
(57011) 
65 M V S Clerk  84,000 Asympto 
matic 
DM,
HT
(F) 
-     - - 110/ 70 158 67 26. 83 91 94 0. 96 171        30 211*  112* +  WNL   - 
27. Sudalai 
Muthu 
(56593) 
56 M NV S Farmer  6000 Leg ulcer - -     - -  170/ 
100 
158 61 24. 43 92 92 1 171       24 253    172 +  WNL   - 
28. Karthikeyan  
(56545) 
47 M NV C Clerk  18000Unexplained
Fatigue 
DM
(F) 
-     - - 100/80 160 80 31.25 95 107 0. 88 260      38 225   130 +  Old AWMI +  
29. Krishnan 
(56719) 
50 M NV S Contract  
Worker  
18000 Delayed 
wound 
healing 
 
- 
 
+   + 
 
- 
 
150/  
110 
 
164 
 
73 
 
27.14 
 
96 
 
99 
 
0. 96 117       32
      
241    157
 
+ 
 Lateral wall  
Ischaemia   
+  
30. Gurusamy  
(56569) 
45 M NV S Security 
Guard 
18000 Giddiness - -     - - 130/ 90 151 70 30.7 94 97 0. 96 135      46 314     274  - Inferior wall  
Ischaemia   
+  
31. V.Jagan  
nathan 
(56859) 
64 M NV S Driver  12000 Asypmto 
matic 
- -     - - 120/ 90 162 58 22. 10 90 93 0. 96 164       50 381*    267  - Inferior wall  
Ischaemia   
+  
32. Maria 
chellathai 
(42017) 
71 F NV IL Housewife  24,000 Polyuria - -     - - 130/ 70 146 48 22.51 101 91 1. 10 134       34 315*   248 +  WNL   - 
33. Venkata 
chalam  
(40859) 
70 M NV S Textile 
worker 
12000Unexplained 
Fatigue 
- +   + - 146/ 90 168 62 21. 95 91 87 1. 04 150      24 210     126 +  Left Atrial 
enlargement 
+ 
 - 
34. Chandra 
sekhar  
(42554) 
52 M NV S Musician  12000 Chest pain - +   + - 110 /80 153 48 20. 50 76 81 0. 93 108      38 205     130  - IWMI  +  
35. Ulaganathan  
(41665) 
45 M NV S Biller,  
Ration Shop 
36000 Polyuria - +   + - 140/ 90 163 66 24. 84 90 88 1. 02 90        38 161*   118* +  Low Voltage 
Complex   
 - 
36. Pitchai 
mydeen 
(41602) 
58 M NV S Co-  
operative 
12000 Breathless 
ness 
- +    - - 130 / 
100 
165 76 27. 91 102 99 1. 03 60        54 163*   111*  - LBBB  +  
37. Jansi 
(40078) 
55 F NV IL Housewife  36000 Chest pain - -     - - 120/ 80 160 58 22. 65 85 90 0.94 167        50 380    132  - Antero septal  
Ischaemia 
+  
38. Ganapathy 
(1177) 
59 M
  
NV S Farmer  10,000 Leg ulcer - -     - - 150/ 90 162 71 27. 05 99 99 1.00 140         64 220*  105*  - Inferior wall  
Ischaemia   
+  
39. Jameela  
(52253) 
47 F NV IL Beedi 
Worker  
6000 Bilateral 
pedal edema
- -     - - 110 /70 148 43 19.63 71 86 0.82 130         58 276   222  - LAHB, VPB 
Anterior Wall 
Ischaemia  
+  
40. Kavitha  
(52610) 
40 M NV S House wife  12000Unexplained
Fatigue 
- -     - - 160 / 90 148 54 24. 65 91 100 0.91 122       70 231    128  - WNL   - 
41. Chandra 
Balan  
(51741) 
54 M NV S Factory  
Worker  
12000 Tingling 
Extremities
- +     - - 140/70 158 62 24.83 88 97 0. 90 162       30 250     128 +  WNL   - 
42. Ganesan  
(52969) 
40 M NV S KTC 
Agent 
18000 Stroke DM 
(M) 
-     - - 110/70 161 51 19.67 79 89 0. 88 140        64 310     248  - Right  
Hemi -paresis 
+  
43. Backiya 
nathan 
(57664) 
63 M NV S Mill worker 6000 Giddiness - -     - - 120/80 171 99 33 .85 109 114 0.95 351       35   311     266 +  WNL   - 
44. Veluchamy 
(39889) 
57 M NV S Tea Estate 
Worker 
30000 Fatigue - -     - - 130/80 
 
160 51 19.92 83 89 0. 93 171       25 355  200 +  Old AWMI, 
IWMI & 
Lateral wall 
Ischaemia 
+  
45. Rajagopala 
Devar(39062) 
65 M NV IL Farmer 18000 Cough - +   + - 130 /80 168 47 16.65 77 85 0.90 100       28 305     218  - WNL    - 
46. Subhiah 
(40080) 
55 M NV S Farmer 12000 Chest pain - -     - - 120/ 80 161 50 19.76 72 81 0.88 126        25 208    171  - WNL   - 
47. Raja(39523) 60 M NV S Railway line 
worker  
12000 Chest pain - +    - - 130 / 80 172 60 20.28 98 98 1 113        34 230    132  - RBBB, LAHB 
Anterior Wall 
Ischaemia 
+  
48. Dharmambal  
(39838) 
75 F V S Housewife  6000 Cough IHD 
(B) 
-     - - 100/ 70 142 58 28.76 92 102 0.9 485        46 270     201 +  IWMI  +  
49. Pandyan 
(37134) 
50 M NV S Driver  18000 Breath- 
lessness 
- +   + - 100/ 70 152 45 19.47 77 82 0. 93 91          58 477    181  - Lateral wall 
Ischaemia  
+  
50. Poova konar 
(39814) 
46 M NV S Farmer  6000 Jaundice HT 
(F) 
-     - - 130 /90 174 92 30.38 112 112 1 139        24 315     180 +  WNL    - 
51. Jayamani 
(39744) 
62 F NV S Housewife  12000 Giddiness - -    - - 120/ 80 146 45 21.11 88 92 0. 95 213       60 578   409  - WNL    - 
52. Chelladurai  
(40115) 
50 M NV S Merchant 9000 Weakness - -     - - 120/ 80 177 68 21.70 83 87 0.95 153      40 208    128  - Left Hemi-
paresis 
+  
53. Swamydoss 
(40598) 
65 M NV S Merchant 18000 Giddiness - +    - - 110/ 80 150 50 22.22 94 86 1.09 188     82 385   136  - WNL   - 
54. Sahul Hameed 
(39813) 
55 M NV S Driver 12000 Leg ulcer,
Visual 
Disturbance
- -     - - 110/ 80 164 75 27.88 94 96 0.97 117     34 277*  131*  - Antero 
Lateral 
Ischaemia 
 
+  
55. Arjunan 
(40016) 
59 M NV S Rtd. Jail 
Supdt. 
36000 Stroke - -     - - 140 / 96 162 65 24.77 86 91 0.94 190      50 196*   122* +  Lateral wall 
Ischaemia / 
Stroke  
+  
56. Chinna 
Karuppa 
samy  
(40494) 
55 M NV S Farmer 24000 Leg ulcer - +    - - 90/60 158 45 18.02 76 82 0.92 94       22  243     129   - WNL   - 
57. Chandra 
sekar 
(42172) 
65 M V S Watchman 12,000 Polyuria - +    - - 180/110 153 58 24.77 99 99 1 127     70  210      171  - LVH,Lateral 
wall ischaemia
+  
58. Arumugam  
(42479)  
58 M NV IL Tailor  24000 Tingling 
Extremities
- -     - - 180/110 150 40 17. 77 72 80 0.9 140     38 216      121 +  Right Axis 
Deviation  
 - 
59. Md. Alibaba 
(42501) 
53 M NV IL Tea stall 
(Master) 
24000 Weight 
loss 
- +   + - 110/80 164 50 18. 81 82 87 0.94 102     34 315      131  - Right Axis 
Deviation 
 - 
60. Chinna samy  
(42476) 
55 M NV IL Carpenter  12000 Delayed 
wound 
healing 
- +   + - 160 / 
100 
163 65 24. 46 82 89 0.92 141      20 201      111 +  Lateral wall  
Ischaemia 
+  
61. Vallithai 
(52744) 
50 F NV IL Farmer 5000 Leg Ulcer - -     - - 100/ 80 147 40 18. 59 62 82 0.75 142     20 252   197  - WNL   - 
62. Abdul Majid 
(38861) 
45 M NV S Driver 12000 Giddiness DM 
 (F) 
-     - - 100/ 80 163 66 24. 84 92 95 0.96 309    46 258    146  - WNL   - 
63. Krishn 
-ammal  
(38897) 
50 F NV S Farmer 10000 Giddiness DM 
(M) 
-     - - 100/ 60 141 39 19. 61 69 85 0.81 140     24 471     201  - WNL   - 
64. Abdul Kadar 
(28660) 
60 M NV S Plastic shop 
Merchant 
12000 Polyuria - -     - - 140/70 158 53 21. 23 112 109 1.02 310     46 249     131 +  Old 
IWMI 
 +  
65. Ramadass 
(542/05) 
71 M NV S Cobbler  6000 Chest pain DM 
(F) 
-      - - 140 /70 149 50 22. 52 84 84 1 185     44 352  264 +  WNL   - 
66. Ponmani  
(540/05) 
57 F NV S Housewife  50000 Visual 
Disturbance
- -     - - 140/ 86 156 72 29. 58 96 112 0. 85 201     28 296  157 +  Inferior, 
Anterior wall 
Ischaemia  
+  
67. Ganapathy  
(57682) 
78 M V S Farmer 12000 Polyuria - -      - - 130 /70 163 55 20.7 83 86 0. 96 80      54 211* 111*  - RBBB   - 
68. Pappa 
(53524) 
45 M NV S Salesman 18000 Polyuria DM 
(F) 
-      - - 110 / 80 156 60 24.65 69 63 1.09 99      26 245    160  - WNL   - 
69. Ganesan 
(45372) 
57 M NV S Sugar 
Factory 
worker  
6000 Un- 
explained 
fatigue 
- -      - - 130/100 150 50 22.22 80 88 0.90 74      38 380  572 +  WNL   - 
70. Dharmalinga 
Nadar (44858) 
65 M NV S Depart 
mental 
Stores  
12000 Chest pain - -     + - 130 / 90 160 60 23.43 92 92 1 141    60 240    130  - Old 
ASMI 
 +  
71 Selvin  
(59571) 
60 M NV S Madura 
coats 
labourer  
24000 Balano 
posthitis 
DM 
(F, D)
-      - -  110/70 160 75 29.29 101 101 1 163     52 230    115  - WNL   - 
72 Esuvadayan 
(44950) 
54 M NV S Fisherman  6000 Un 
explained 
Fatigue 
- +    + - 130/90 160 48 18.75 71 71 1 101    72 239     146  - WNL   - 
73 Susheela  
(61510) 
50 F V S Farmer  12000 Polyuria -  -     - - 110/80 152 45 19.47 78 80 0.97 262    50 219    220  - WNL   - 
74 Sandhana 
Sundhari  
(1708/05) 
47 F NV S Housewife  12000 Vitiligo - -      - -   120/80 145 70 33.29 109 109 1 117    55 260    179  - WNL   - 
75 Arunachalam  
 (30469) 
70 M V IL   Coolie 10000 Fatigue - -      - -  110/70 150 45 20 80 86 0.93 147    68 399     130  - WNL   - 
76 Indira  
(61506) 
55 F V S Housewife 18000 Polyuria - -      - - 110/70 140 40 20.4 74 84 0.88 141    42 230     118  - WNL   - 
77 Abdul Salam 
(35482) 
35 M NV S Cook 12000 Weakness 
of right 
extremities
- -      - - 130/90 162 62 23.62 86 90 0.95 130     54 240     126  - Right 
hemiparesis 
+  
78 Mohammed 
Ibrahim 
(44487) 
65 M NV S Cleric  6000 Fatigue - -      - - 146/80 158 60 24.03 84 88 0.95 74      26 318     227 +  Old IWMI +  
79 Subbulakshmi 
(44728) 
61 F NV S Housewife 7500 Tingling 
extremities
DM 
(S) 
-      - - 170/110 143 67 32.76 104 107 0.97 185    34 245    153 +  Old ASMI +  
80 Pookani  
(58806) 
43 F NV S VHN 48000 Polyuria DM 
(M) 
-      - - 100/70 151 52 22.80 89 99 0.89 81      36 240    133 +  Old ASMI +  
81 Saraswathi  
(57201) 
60 F V S Housewife 12000 Polyuria DM 
(M, B) 
HT 
(M) 
-      - - 150/90* 142 55 27.27 87 99 0.87 221    36 305    161 +  WNL   - 
82 Saroja  
(57228) 
53 F NV IL Housewife  60000 Pruritus 
vulvae 
- -      - - 170/90 144 80 38.58 105 115 0.91 337    16 235    140 +  Anterolateral  
Ischaemia 
+  
83 Annammal 
(57357) 
52 F NV S Housewife 24000 Pruritus 
vulvae 
DM 
(B) 
-      - - 130/70 141 57 28.67 84 90 0.93 165     50 370     267  - Inferior wall 
Ischaemia  
+  
84. Eswarath- 
ammal 
(58190) 
50 F V IL Cottage  
Industry 
18000 Unexplained 
vomiting 
- -      - -  120/70 143 50 24.45 84 94 0.89 187    46 390     310 +  WNL   - 
85 Rama 
chandran 
(58559) 
65 M NV S Watchman  10000 Polyuria - -      - - 120/80 162 65 24.76 96 90 1.06  103     26 357     140  - WNL   - 
86 Murugan 
(58795) 
40 M V S Hotel 
Supplier  
12000 Polyuria 
Visual 
Disturbance
DM 
(M, B)
-      - - 140/90 165 75 27.54 105 106 0.99 97     24 311     227 +  WNL   - 
87 Mydeen 
Fatima  
(45014) 
45 F NV S Beedi  
worker  
6000 Breath 
lessness 
- -      - - 140/80 138 48 25.2 85 87 0.97 125    16 201* 114* +  Sinus   
tachycardia  
 - 
88. Vallithai  
(58213) 
56 F NV S Housewife  24000 Vomiting - -      - - 170/100 140 50 25.1 90 98 0.91 194     30 237     120 +  Old IWMI 
Anterolateral 
Ischaemia 
+  
89 Alagu 
Rathinam  
(57195) 
56 M NV S Driver  1,10,000 Unexplai-
ned 
fatigue 
DM
(F,M)
-      - - 140/90 163 74 27.85 98 98 1 172   34 233    149 +  WNL   - 
90 Gomathi  
(45002) 
65 F V IL Small scale 
Industry 
worker  
10,000 Polyuria - -      - - 150/100 148 54 24.65 102 102 1 181     24 270     188 +  Lateral wall 
Ischaemia  
+  
91 Farida Begum
(590/05) 
47 M NV S House wife  36000 Weight 
loss 
- -      - - 140/110 153 70 29.9 98 112 0.87 404     30 255     151 +  WNL   - 
92 Josephine  
(56842) 
65 F NV S House wife 12000 Giddiness - -      - - 140/90 150 45 20 76 83 0.91 198    22 324     210 +  WNL   - 
93 Rajammal 
(57231) 
60 F NV S House wife 12000 Giddiness - -      - - 156/110 142 66 32.73 102 113 0.90 240     42 232     129 +  Lateral wall 
Ischaemia 
+  
94 Murugan 
(57162) 
50 M NV C Panchayat 
clerk 
24000 Polyuria - -      - - 120/90 158 76 30.44 99 103 0.96 357    20 245     140 +  WNL   - 
95 Muthammal 
(36656) 
45 F NV IL House wife 18000 Leg ulcer - -      - - 110/80 163 44 16.56 76 82 0.92 102     16 261     138  - WNL   - 
96 Avudayappan 
(1457/05) 
45 M NV S Market  
coolie 
18000  Stricture 
urthera 
- -      - - 130/90 157 90 36.51 107 113 0.94 158    22 273    159 +  WNL   - 
97 Poovammal 
(468/05) 
57 F NV S House wife 12000 Polyuria - -      - - 120/80 156 58 23.83 100 96 1.04 464     16 209    130 +  WNL   - 
98 Saraswathi 
(472/05) 
60 F NV S House wife 4000 Fatigue - -      - - 120/80 144 50 24.11 84 86 0.97 110     56 223     112  -  Inferior wall 
Ischaemia  
+  
99 J. Rosemary  
(10655) 
52 F NV S Tailor 5000 Dental 
caries 
- -      - - 130/80 154 55 23.19 85 100 0.85 130     54 301     239  - Lateral wall 
Ischaemia 
+  
100 Petchiammal 55 F NV S House wife  12000 Asymptom
atic 
- -      - - 120/80 145 50 23.78 84 95 0.88 140    45 279     248  - WNL   - 
 
Sex :    M -   Male Literacy :   C   - College Family History :    F – Father Personal History   S – Smoker Ht – Height  WC – Waist circumference  
    F   -  Female      S   – School   M – Mother   A – Alcoholic Wt – Weight  HC – Hip circumference 
        IL  - Illiterate   B – Brother     BMI – Body Mass Index WHR – Waist Hip Ratio 
        S – Sister 
Food Habit :  V   – Vegetarian 
        NV – Non Vegetarian      ECG : Electro Cardiogram     
WNL – Within normal Limits   LBBB – Left Bundle Branch Block 
BS – Blood Sugar  CVD – Cardiovascular    ASMI – Antero septal myocardial infarction  LAHB – Left Anterior Hemi Block    
R – Random                (Coronary / Cerebro vascular) events  IWMI – Inferior wall myocardial infarction  LVH    : Left Ventricular Hypertrophy 
F – Fasting  TIA – Transient Ischaemic attack   AWMI : Anterior Wall myocardial infarction  VPB     - Vaentricular premature beat 
   CVA – Cerebro vascular accident            
                    
          
